Barbara Trebbi
Known title: DirectorCIK: 0001730619
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
AAMI Clears Minervini Trend Template, Analysts Raise Targets. AAMI has recently cleared the Minervini Trend Template, indicating strong upward momentum. Evercore ISI Group and RBC Capital both raised their price targets, to $102 and $85 respectively, while maintaining a sector‑perform rating. The stock sits near its 52‑week high and is trading above a key support level of $90.79, with an RSI of 53.
Transaction History
| BLCO | ▲ Buy | Grant | 11,776 | $0 | 8/12/2026 | View on chart |
| AAMI | ▼ Sell | Gift | 10,260 | $0 | 6/15/2026 | View on chart |
| AAMI | ▼ Sell | Gift | 10,260 | $0 | 6/15/2026 | View on chart |
| AAMI | ▲ Buy | Option Exercise | 3,286 | $0 | 5/14/2026 | View on chart |
| AAMI | ▼ Sell | Open Market | 9,691 | $496K | 2/10/2026 | View on chart |
| AAMI | ▲ Buy | Option Exercise | 4,437 | $0 | 5/13/2025 | View on chart |
| AAMI | ▲ Buy | Option Exercise | 4,379 | $0 | 6/6/2024 | View on chart |
| AAMI | ▲ Buy | Option Exercise | 4,762 | $0 | 6/7/2023 | View on chart |
| AAMI | ▲ Buy | Option Exercise | 4,193 | $0 | 6/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
BLCO Advances Oral Dry AMD Treatment After FDA Meeting
Bausch + Lomb reported progress on a new oral drug for dry age‑related macular degeneration after a constructive meeting with the FDA. The company said the discussion helped clarify the regulatory pathway and the drug’s development plan. It also announced that its third‑quarter 2026 earnings will be released on Oct. 28, giving investors a future update on performance.
BLCO Advances Oral Dry AMD Treatment After FDA Meeting. Bausch + Lomb reported progress on a new oral drug for dry age‑related macular degeneration after a constructive meeting with the FDA. The company said the discussion helped clarify the regulatory pathway and the drug’s development plan. It also announced that its third‑quarter 2026 earnings will be released on Oct. 28, giving investors a future update on performance.